Boston Scientific Announces FDA Clearance and U.S. and European Availability of WallFlex(R) Biliary RX Cove...(ts within the meaning of Section 21E of ...),Health

Date:10/6/2009

ts within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things our product performance, regulatory approval of our products, competitive offerings, our growth strategy, and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Fact
'/>"/>

SOURCE Boston Scientific Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
2. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
3. The 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA -- Hynes Convention Center October 31 -- November 3, 2009
4. SPIRIT IV Results Reaffirm Strong Performance of Boston Scientific PROMUS(R) and TAXUS(R) Express(R) Stents
5. Boston Scientific Announces Schedule for European Society of Cardiology Congress
6. Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial
7. Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
8. Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
9. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
10. Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientifics TAXUS(R) Liberte(R) Stent
11. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine